European Matchmaking event – Development and production of COVID-19 therapeutics

Medicines for COVID-19 are still in the development phase. Therefore, the objective of the event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication in treatment of COVID-19, at all stages of COVID-19 disease and mobilise the EU pharma manufacturing capacity for their potential production.

The target group is the entire EU COVID-19 therapeutics value chain starting with researchers and developers, through manufacturing companies and representatives of the hospitals, who apply such therapeutics to their patients. The providers of ancillary functions such as clinical trials services, accessories suppliers (e.g. vials, syringes, tubes etc.), funding providers and public procurers will also be targeted to take part in the event.